Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
CNTA Logo

Centessa Pharmaceuticals Plc

CNTA

Pharmaceutical Preparations

Mkt Cap

$809.1M

PE

-5.85

Debt

$76.8M

Cash

$118.2M

EV

$767.7M

FCF

-$149.9M

Market Cap

$809.1M

P/E Ratio

-5.85

Debt

$76.8M

Cash

$118.2M

EV

$767.7M

FCF

-$149.9M
Charts data: {"Earnings":[{"time":"2019-12-30","value":-5061000},{"time":"2020-12-30","value":-10663000},{"time":"2021-12-30","value":-381071000},{"time":"2022-12-30","value":-216207000},{"time":"2023-12-30","value":-151085000}],"Sales":[{"time":"2022-12-30","value":0},{"time":"2023-12-30","value":6853000}],"Net Margins":[{"time":"2023-12-30","value":-22.046548956661315}],"Assets":[{"time":"2020-12-30","value":11717000},{"time":"2021-12-30","value":629635000},{"time":"2022-12-30","value":444307000},{"time":"2023-12-30","value":360246000}],"Stockholders Equity":[{"time":"2019-12-30","value":-11857000},{"time":"2020-12-30","value":-22423000},{"time":"2021-12-30","value":491554000},{"time":"2022-12-30","value":336169000},{"time":"2023-12-30","value":236244000}],"ROE":[{"time":"2019-12-30","value":0.4268364679092519},{"time":"2020-12-30","value":0.4755385095660706},{"time":"2021-12-30","value":-0.7752373086171611},{"time":"2022-12-30","value":-0.6431497252869837},{"time":"2023-12-30","value":-0.6395294695315014}],"ROA":[{"time":"2020-12-30","value":-0.8910130579499872},{"time":"2021-12-30","value":-0.5941283441994171},{"time":"2022-12-30","value":-0.47773949093757245},{"time":"2023-12-30","value":-0.47546121261582364}]}

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Sector

  • ABBV Logo

    ABBV

  • ABCL Logo

    ABCL

  • ABT Logo

    ABT

  • ABUS Logo

    ABUS

  • ACAD Logo

    ACAD

  • AGIO Logo

    AGIO

  • AKRO Logo

    AKRO

  • ALKS Logo

    ALKS

  • ALNY Logo

    ALNY

  • ALPN Logo

    ALPN

  • AMPH Logo

    AMPH

  • AMRN Logo

    AMRN

  • AMRX Logo

    AMRX

  • ANAB Logo

    ANAB

  • ANIP Logo

    ANIP

  • ARCT Logo

    ARCT

  • ARDX Logo

    ARDX

  • ARQT Logo

    ARQT

  • ARVN Logo

    ARVN

  • ARWR Logo

    ARWR

  • AUPH Logo

    AUPH

  • AVDL Logo

    AVDL

  • AVIR Logo

    AVIR

  • AVTE Logo

    AVTE

  • AXSM Logo

    AXSM

  • BBIO Logo

    BBIO

  • BCYC Logo

    BCYC

  • BGNE Logo

    BGNE

  • BHVN Logo

    BHVN

  • BMEA Logo

    BMEA

  • BMRN Logo

    BMRN

  • BMY Logo

    BMY

  • BPMC Logo

    BPMC

  • CDMO Logo

    CDMO

  • CERE Logo

    CERE

  • CMPS Logo

    CMPS

  • COGT Logo

    COGT

  • COLL Logo

    COLL

  • CORT Logo

    CORT

  • CPRX Logo

    CPRX

  • CRNX Logo

    CRNX

  • CYRX Logo

    CYRX

  • CYTK Logo

    CYTK

  • DAWN Logo

    DAWN

  • DCPH Logo

    DCPH

  • DVAX Logo

    DVAX

  • DYN Logo

    DYN

  • ELAN Logo

    ELAN

  • EOLS Logo

    EOLS

  • ERAS Logo

    ERAS

  • ETNB Logo

    ETNB

  • EWTX Logo

    EWTX

  • FOLD Logo

    FOLD

  • GERN Logo

    GERN

  • GPCR Logo

    GPCR

  • HRMY Logo

    HRMY

  • HROW Logo

    HROW

  • HZNP Logo

    HZNP

  • IDYA Logo

    IDYA

  • IGMS Logo

    IGMS

  • INSM Logo

    INSM

  • INVA Logo

    INVA

  • IONS Logo

    IONS

  • IRON Logo

    IRON

  • IRWD Logo

    IRWD

  • ITCI Logo

    ITCI

  • JANX Logo

    JANX

  • JAZZ Logo

    JAZZ

  • JNJ Logo

    JNJ

  • KALV Logo

    KALV

  • KNSA Logo

    KNSA

  • KROS Logo

    KROS

  • KURA Logo

    KURA

  • LGND Logo

    LGND

  • LLY Logo

    LLY

  • LQDA Logo

    LQDA

  • LXRX Logo

    LXRX

  • LYEL Logo

    LYEL

  • MDGL Logo

    MDGL

  • MIRM Logo

    MIRM

  • MLTX Logo

    MLTX

  • MLYS Logo

    MLYS

  • MNKD Logo

    MNKD

  • MORF Logo

    MORF

  • MRK Logo

    MRK

  • MRUS Logo

    MRUS

  • MRVI Logo

    MRVI

  • NRIX Logo

    NRIX

  • OCUL Logo

    OCUL

  • OGN Logo

    OGN

  • OLMA Logo

    OLMA

  • OPK Logo

    OPK

  • ORGO Logo

    ORGO

  • ORIC Logo

    ORIC

  • PAHC Logo

    PAHC

  • PBAJ Logo

    PBAJ

  • PBH Logo

    PBH

  • PCRX Logo

    PCRX

  • PFE Logo

    PFE

  • PGEN Logo

    PGEN

  • PHAT Logo

    PHAT

  • PLRX Logo

    PLRX

  • PRGO Logo

    PRGO

  • PRTA Logo

    PRTA

  • PTCT Logo

    PTCT

  • PTGX Logo

    PTGX

In the chart Earnings are multiplied by this value.

Earnings Growth -
Earnings Stability -


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201912-202012-202112-202212-2023TTM
Net Margin-----2.2K%-
ROA--89%-59%-48%-48%-48%
ROE43%48%-78%-64%-64%-64%

What is the average Net Margin?

The average Net Margin over the past 5 years is -2.2K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -47.55%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -63.95%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201912-202012-202112-202212-2023TTM
Debt FCF--0.53-0.56-0.35-0.47-0.51
Debt Equity--0.250.150.210.320.36
MIN
Graham Stability------

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -0.51.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-202012-2022Trend
Revenue---
Net Income---
Stockholders Equity--30%1.9%
FCF---

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +1.89%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.